6Clinical and Laboratory Standards Institute.Performance standarch for antimicmbial susceptibility testing,16th informational supplement[S].CLSI,M100-S16,Wayne,PA,2006,26-28.
7Kotloff K L,Winickoff J P,Ivanoff B,et al.Global burden of Shigella infections:implications for vaccine development and implementation of control strategies[J].Bull World Health Organ,1999,77(8):651-666.
8Venkatesan M,Fernandez-Prada C,Buysse J M,et al.Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain[J].Vaccine,1991,9(5):358-363.
9Gupta A,Polyak C S,Bishop R D,et al.Laboratory-confirmed Shigellosis in the United States,1989.2002:epidemiologic trends and patterns[J].Clin Infect Dis,2004,38(10):1372-1377.
